AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04957290
Drug: NOX66
RxNorm normalized name: Noxafil
DrugBank: Posaconazole (DB01263)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: NOX66 1600 mg daily (800 mg suppository BID).
Trial: NCT04957290
Drug: NOX66
RxNorm normalized name: Noxafil
DrugBank: Posaconazole (DB01263)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: NOX66 2400 mg daily (1200 mg suppository BID).
Trial: NCT04957290
Drug: NOX66
RxNorm normalized name: Noxafil
DrugBank: Posaconazole (DB01263)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: NOX66 RP2D
Trial: NCT04345666
Drug: Testosterone cypionate
RxNorm normalized name: Testosterone Cypionate
DrugBank: Testosterone cypionate (DB13943)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The intervention of this study is to treat patients to either 1) testosterone cypionate or 2) placebo (sterile saline) to determine if there is a difference in recovery times after arthroscopic rotator cuff repair
Trial: NCT05458765
Drug: emtricitabine/tenofovir alafenamide
RxNorm normalized name: Emtricitabine/Tenofovir Alafenamide 200 MG-25 MG Oral Tablet
DrugBank: Emtricitabine (DB00879)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 200mg/25mg tablet, once daily dosing for 24 weeks
Trial: NCT05458765
Drug: Emtricitabine / Tenofovir Disoproxil Oral Tablet
RxNorm normalized name: emtricitabine / tenofovir disoproxil Oral Tablet
DrugBank: Tenofovir disoproxil (DB00300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 200mg/300mg tablet, once daily dosing for 24 weeks
Trial: NCT05005494
Drug: Magnesium sulfate IV
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium sulfate (DB00653)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Infusion of magnesium sulphate 50 mg/kg (eq. 0.5ml/kg of magnesium sulphate 100mg/ml)
Trial: NCT05984342
Drug: Tislelizumab
RxNorm normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant Chemotherapy （nab-paclitaxel 260mg/m2 d1 plus Cisplatin 75mg/m2 d1 or 25mg/m2 d1-3) in combination with Tislelizumab (200 mg Q3W)
Trial: NCT05886933
Drug: Fexuprazan Hydrochloride
RxNorm normalized name: Chlorpromazine Hydrochloride
DrugBank: Chlorpromazine (DB00477)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patient treated with Fexuprazan Hydrochloride (Fexuclue Tablet)
Trial: NCT04943445
Drug: carboplatin AUC of 6, paclitaxel 175 mg/m2, and pembrolizumab 200 mg, i.v. on day 1, every 21 days for 3 cycles
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients without disease progression will proceed to the concurrent radioimmunotherapy phase of the trial.
Trial: NCT04943445
Drug: Consolidation immunotherapy: pembrolizumab 200 mg i.v. on day 1, every 21 days for 11 doses.
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Consolidation immunotherapy
Trial: NCT04897477
Drug: Azacytidine, Bendamustine and Piamprizumab
DrugBank: Cytidine (DB02097)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azacytidine by means of subcutaneous injection, Bendamustine and Piamprizumab intravenous infusion
Trial: NCT05332496
Drug: PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: PD-1/PD-L1 inhibitors: atezolizumab, sintilimab, pembrolizumab, nivolumab, camrelizumab, tislelizumab, toripalimab, durvalumab, penpulimab, and other ICIs; VEGF-TKI/bevacizumab: sorafenib, lenvatinib, donafenib, apatinib, anlotinib, bevacizumab/ bevacizumab biosimilar, and other anti-angiogenesis drugs; Both PD-1/PD-L1 inhibitors and anti-angiogenesis drugs only include marketed drugs but are not limited to HCC approval.
Trial: NCT05182476
Drug: Luvadaxistat
RxNorm normalized name: Luvadaxistat
DrugBank: Luvadaxistat (DB16067)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablets
Trial: NCT05526989
Drug: Dostarlimab
RxNorm normalized name: Dostarlimab
DrugBank: Dostarlimab (DB15627)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 300 mg Dostarlimb will be administered by IV, increasing to 1000 mg after cycle 4.
Trial: NCT05526989
Drug: Niraparib
RxNorm normalized name: Niraparib
DrugBank: Niraparib (DB11793)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 200 mg Niraparib will be taken once daily by mouth days 1-21 of all cycles.
Trial: NCT06191744
Drug: Epcoritamab
RxNorm normalized name: Epcoritamab
DrugBank: Epcoritamab (DB16672)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous (SC) Injection
Trial: NCT06191744
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral Tablet
Trial: NCT06191744
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous (IV) Infusion
Trial: NCT06191744
Drug: Lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral Capsule
Trial: NCT06191744
Drug: Vincristine
RxNorm normalized name: Vincristine
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV Injection
Trial: NCT06191744
Drug: Obinutuzumab
RxNorm normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: IV Infusion
Trial: NCT06191744
Drug: Bendamustine
RxNorm normalized name: Bendamustine
DrugBank: Bendamustine (DB06769)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV Infusion
Trial: NCT05218486
Drug: Isotretinoin
RxNorm normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isotretinoin is a vitamin-A derivative for treatment of moderate to severe acne used in a dose from 20-40 mg for 3 months duration
Trial: NCT04755075
Drug: Surufatinib
RxNorm normalized name: Surufatinib
DrugBank: Surufatinib (DB15106)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects to receive Surufatinib 250 mg on Day 1
Trial: NCT06017479
Drug: Fosfomycin 3000 MG
RxNorm normalized name: fosfomycin 3000 MG
DrugBank: Fosfomycin (DB00828)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fosfomycin 3 g single dosage 1 hour before the urodynamic examination
Trial: NCT06017479
Drug: Levofloxacin 500mg
RxNorm normalized name: LEVOFLOXACIN 500MG TAB
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Levofloxacin 500 mg single dosage 1 hour before the urodynamic examination
Trial: NCT05764057
Drug: Dapagliflozin propanediol (FORXIGA™/FARXIGA™1)
RxNorm normalized name: Dapagliflozin Propanediol
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dapagliflozin (10 mg per day; per os) on top of standard of care as recommended in current guidelines\* for 6 months (experimental group)~\*All patients will receive optimal medical therapy (including antithrombotic, beta-blockers, statins, angiotensin converting enzyme inhibitors or angiotensin receptor blocker or sacubitril/valsartan, diuretics, antagonists of the mineralocorticoid receptor) according to their clinical condition as recommended.
Trial: NCT06159959
Drug: Carbetocin
RxNorm normalized name: Carbetocin
DrugBank: Carbetocin (DB01282)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: To assess the effectiveness of single IV bolus dose of carbetocin in the prevention of primary PPH in obese versus non obese women undergoing elective cesarean section.
Trial: NCT04843449
Drug: Itraconazole
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral capsules
Trial: NCT04843449
Drug: rifampicin
RxNorm normalized name: Rifampicin
DrugBank: Rifampin (DB01045)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral capsules
Trial: NCT05439148
Drug: OPC-61815 injection
RxNorm normalized name: OPC-14523
DrugBank: OPC-14523 (DB05422)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of OPC-61815 at 8 mg or 16 mg. 8mg group will be intravenously administered only on D1, once a day. 16mg group will be intravenously administered on D1，D3-D9, once a day.
Trial: NCT04702971
Drug: Flunarizine
RxNorm normalized name: flunarizine
DrugBank: Flunarizine (DB04841)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The flunarizine will be given per clinical routine
Trial: NCT05611593
Drug: Propecia 1Mg Tablet
RxNorm normalized name: Propecia 1mg Tablet
DrugBank: Finasteride (DB01216)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral Finasteride
Trial: NCT04703673
Drug: Cineole
RxNorm normalized name: Cineole
DrugBank: Eucalyptol (DB03852)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: self administration according to directions for use
Trial: NCT04703673
Drug: Nasal Decongestant
RxNorm normalized name: Nasal Decongestant
DrugBank: Phenylephrine (DB00388)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: self administration according to directions for use
Trial: NCT06777511
Drug: 5-aminolevulinic acid (5-ALA)
DrugBank: Aminolevulinic acid (DB00855)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All patients who are recruited and enrolled into this study use topical 5- ALA, in combination with the light delivery device as part of their standard stoma management.
Trial: NCT04717414
Drug: ACE-536
RxNorm normalized name: lithium acetate 536 MG
DrugBank: Lithium citrate (DB14507)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subcutaneous Injection
Trial: NCT05554627
Drug: Esketamine
RxNorm normalized name: ESKETAMINE
DrugBank: Esketamine (DB11823)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intranasal spray; a dissociative hallucinogen drug used as a general anesthetic and an antidepressant for treatment of depression.
Trial: NCT05554627
Drug: Aripiprazole
RxNorm normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Atypical antipsychotic; used in the treatment of schizophrenia and bipolar disorder. Other uses include as an add-on treatment in major depressive disorder, tic disorders and irritability associated with autism. Taken by mouth or injection into a muscle.
Trial: NCT05242692
Drug: S-ketamine
RxNorm normalized name: S-ketamine
DrugBank: Esketamine (DB11823)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Loading dose: 0.25mg/kg in 10 minutes Maintenance dose: 0.1mg/kg/h
Trial: NCT05242692
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Loading dose: 0.2 ug/kg in 10 minutes Maintenance dose: 0.2 ug/kg/h
Trial: NCT06054191
Drug: Dabrafenib + Trametinib
RxNorm normalized name: Dabrafenib
DrugBank: Trametinib (DB08911)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dabrafenib 150mg BID + Trametinib 2mg QD/（2 cycles）
Trial: NCT06054191
Drug: Capmatinib
RxNorm normalized name: CAPMATINIB
DrugBank: Capmatinib (DB11791)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capmatinib 400mg BID/（2 cycles）
Trial: NCT06319313
Drug: JMT101
RxNorm normalized name: Jmt101 (fully human monoclonal igg1 antibody targeting epidermal growth factor receptor (egfr))
DrugBank: Becotatug (DB19069)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JMT101, 6 mg/kg, IV infusion once every 2 weeks (one treatment cycle is 4 weeks). or 9 mg/kg, IV infusion once every 3 weeks.
Trial: NCT06319313
Drug: docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 mg/m2, IV infusion once every 2 weeks (one treatment cycle is 4 weeks). Or 75 mg/m2, IV infusion once every 3 weeks.
Trial: NCT05140655
Drug: Fulvestrant
RxNorm normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Medicine for Advanced breast cancer
Trial: NCT05507775
Drug: Digoxin tablet
RxNorm normalized name: Digoxin Tablets
DrugBank: Digoxin (DB00390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will be treated with digoxin tablets for 3 weeks. On the first they, participants will start with a starting dosage of 3x0.25mg with 6 hours between each administration. Thereafter they will continue with a dosage of 1x0.25mg. Participants aged \>70 years or with body weight \<55kg will initiate a starting dosage of 3x0.125mg with 6 hours between each administration. Thereafter they will continue with a dosage of 1x0.125mg.~After one week the blood concentration of digoxin will be measured. According to this blood concentration, the dose of digoxin will be adjusted.
Trial: NCT06225427
Drug: Gilteritinib
RxNorm normalized name: Gilteritinib
DrugBank: Gilteritinib (DB12141)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT04408144
Drug: Dydrogesterone 10mg Oral Tablet
RxNorm normalized name: dydrogesterone 10 MG
DrugBank: Dydrogesterone (DB00378)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral 10mg dydrogesterone (Duphaston) 2 times daily
Trial: NCT05354479
Drug: Paracetamol
RxNorm normalized name: Paracetamol
DrugBank: Acetaminophen (DB00316)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: babies will get expressed breast milk along with paracatamol for pain relief
Trial: NCT04854434
Drug: Selinexor
RxNorm normalized name: Selinexor
DrugBank: Selinexor (DB11942)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Participants will receive selinexor oral tablets.
Trial: NCT04854434
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive pembrolizumab intravenously.
Trial: NCT04854434
Drug: Trifluridine
RxNorm normalized name: Trifluridine
DrugBank: Trifluridine (DB00432)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will receive trifluridine oral tablets as SOC.
Trial: NCT04854434
Drug: Tipiracil
RxNorm normalized name: Tipiracil
DrugBank: Tipiracil (DB09343)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will receive tipiracil oral tablets as SOC.
Trial: NCT04783051
Drug: Sulfadoxine pyrimethamine
RxNorm normalized name: pyrimethamine / sulfadoxine
DrugBank: Pyrimethamine (DB00205)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intermittent Preventive Treatment in pregnant women with Sulfadoxine-Pyrimethamine
Trial: NCT06370754
Drug: JS004
RxNorm normalized name: Immunoglobulin g4, anti-(human b and t lymphocyte attenuator (btla)) (human-mus musculus monoclonal js004 .gamma.4-chain), disulfide with human-mus musculus monoclonal js004 .kappa.-chain, dimer
DrugBank: Tifcemalimab (DB18914)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg by IV infusion Q3W, given on cycle day 1.
Trial: NCT06370754
Drug: JS007
RxNorm normalized name: Imatinib
DrugBank: Imatinib (DB00619)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 3mg/kg by IV infusion Q3W, given on cycle day 1.
Trial: NCT06370754
Drug: Irinotecan Liposome Injection
RxNorm normalized name: Irinotecan liposome injection
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 60 or 70 mg/m\^2 by IV infusion every 2 weeks (Q2W), given on cycle day 1.
Trial: NCT06370754
Drug: 5-Fluorouracil (5-FU)
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2400mg/m\^2, intravenously, over 46 h on day 1, Q2W.
Trial: NCT06370754
Drug: Nab paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 125 mg/m\^2 by IV infusion Q3W, given on cycle day 1 and 8.
Trial: NCT06370754
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000 mg/m\^2 by IV infusion Q3W, given on cycle day 1 and 8.
Trial: NCT06054178
Drug: Fluorescein Sodium
RxNorm normalized name: Fluorescein Sodium
DrugBank: Fluorescein (DB00693)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous administration of 1 mg/kg. If initial dosing is insufficient, additional doses may be administered up to a total of 3 mg/kg
Trial: NCT05541276
Drug: Isotonic sodium chloride solution
RxNorm normalized name: ISOTONIC SODIUM CHLORIDE SOLUTION
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium chloride 0.9 % for injection
Trial: NCT05249114
Drug: Cabozantinib
RxNorm normalized name: Cabozantinib
DrugBank: Cabozantinib (DB08875)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Cabozantinib tablets are supplied as film coated tablets containing cabozantinib malate equivalent to 20 mg and 60 mg of cabozantinib and contain microcrystalline cellulose, lactose anhydrous, hydoxypropyl cellulose, croscarmellose sodium, colloidal silicon dioxide, magnesium stearate and Opadry yellow. The 60 mg tablets are oval and the 20 mg tablets are round. Doses of 40 mg will comprise two 20-mg tablets.
Trial: NCT05249114
Drug: Lu-177
RxNorm normalized name: Lu-177
DrugBank: Lutetium Lu-177 (DB13982)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Currently, the only FDA-approved PRRT consists of dotatate, a somatostatin analogue, radiolabeled with Lutetium-177 (Lu177), a beta-minus emitter (brand name Lutathera). Lu177 induces cell death via DNA strand breaks, caspase-3 apoptosis, and interfering with DNA-PK expression (which is associated with DNA repair). PRRT with Lu-177 DOTATATE is a targeted, intravenous therapy inducing DNA damage by delivering ionizing radiation to somatostatin receptor positive tumors.
Trial: NCT05818852
Drug: VX-548
RxNorm normalized name: VX-121
DrugBank: Vanzacaftor (DB18373)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets for oral administration.
Trial: NCT05818852
Drug: Moxifloxacin
RxNorm normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Capsules for oral administration.
Trial: NCT05818852
Drug: Moxifloxacin Placebo
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Capsules for oral administration.
Trial: NCT05352815
Drug: Insulin icodec
RxNorm normalized name: insulin icodec
DrugBank: Insulin icodec (DB16693)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive once weekly Insulin icodec subcutanously (s.c. under the skin) with or without oral anti diabetic drugs for 52 weeks.
Trial: NCT06199505
Drug: insulin degledec/insulin aspart
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Once daily or twice daily
Trial: NCT05873881
Drug: Colchicine 0.5 MG
RxNorm normalized name: colchicine 0.5 MG
DrugBank: Colchicine (DB01394)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral colchicine 0.5 mg daily
Trial: NCT05873881
Drug: Colchicine placebo
RxNorm normalized name: Colchicine
DrugBank: Colchicine (DB01394)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Placebo colchicine daily
Trial: NCT05039281
Drug: Cabozantinib
RxNorm normalized name: Cabozantinib
DrugBank: Cabozantinib (DB08875)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT06569394
Drug: Broad Spectrum Cannabidiol (bsCBD) 400 mg
RxNorm normalized name: CANNABIDIOL
DrugBank: Cannabidiol (DB09061)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Participants in this Arm will take 400 mg of bsCBD daily. Participants will take medication by mouth with food in the morning and evening.
Trial: NCT06378242
Drug: Disitamab Vedotin for injection
RxNorm normalized name: Brentuximab Vedotin
DrugBank: Disitamab vedotin (DB17208)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravesical instiliations into the bladder
Trial: NCT05666336
Drug: Hydroxychloroquine
RxNorm normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: It is necessary and will be given by oral administration of 0.2g/day for 24 weeks.
Trial: NCT05666336
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: It is permitted which can be interchangeable with methylprednisolone. It will be given by oral administration of 30mg/day from beginning and be lowed dosage during the treatment of 24 weeks.
Trial: NCT05666336
Drug: Methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: It is permitted which can be interchangeable with prednisone. It will be given by oral administration of 24mg/day from beginning and be lowed dosage during the treatment of 24 weeks.
Trial: NCT05666336
Drug: Mycophenolate Mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: It is permitted which can be interchangeable with cyclophosphamide or tacrolimus. It will be given by oral administration of 0.5g twice a day for 24 weeks.
Trial: NCT05666336
Drug: Tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: It is permitted which can be interchangeable with cyclophosphamide or mycophenolate mofetil. It will be given by oral administration of 1mg twice a day for 24 weeks.
Trial: NCT02712151
Drug: Ropivacaine 0.2%
RxNorm normalized name: ROPivacaine 0.2% injectable solution
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ropivacaine 0.2% 1.0 ml/kg total in divided doses for bilateral TAP and RS blocks.
Trial: NCT02712151
Drug: Ropivacaine 0.5%
RxNorm normalized name: ROPivacaine 0.5% injectable solution
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ropivacaine 0.5% 0.4 ml/kg total in divided doses distributed between the 4 laparoscopic port sites
Trial: NCT00502073
Drug: cyclosporine
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04878770
Drug: Systemic cyclosporine
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic cyclosporine A (CsA) is an immunosuppressive therapy and is a registered treatment for AD in adults. According to national guidelines, CsA is the first choice for systemic treatment in children with moderate-to-severe AD.~For CsA a starting dose of 4-5mg/kg/day is administered orally and then tapered down to 2-3mg/kg/day depending on clinical effect. Two doses will be taken at two fixed times per day. Treatment with systemic CsA will be continued for a total of 6 months.